eligibility_summary
Adults (≥18) with advanced solid tumors, RECIST-measurable disease, prior adequate therapy, ECOG 0–1, life expectancy ≥12 weeks, adequate organs, and tumor tissue/biopsy available, contraception and (for women) pregnancy tests required. Exclude: spinal cord compression, brain mets unless stable/asymptomatic/low steroids, unresolved ≥G2 AEs, uncontrolled infections (controlled HBV/HCV/HIV allowed), ILD/pneumonitis, major cardiac disease/QTcF>470, uncontrolled illness, recent live vaccine, pregnancy/lactation, other trials, hypersensitivity, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/IIa modular study of AZD5335, an IV antibody-drug conjugate (ADC), as monotherapy or combined with: saruparib (AZD5305, oral PARP1‑selective inhibitor), AZD9574 (oral PARP inhibitor), bevacizumab (IV anti‑VEGF‑A monoclonal antibody), and carboplatin (IV platinum DNA‑crosslinker). Mechanisms: AZD5335 binds a tumor‑associated surface antigen and delivers an intracellular cytotoxic payload to kill antigen‑expressing cancer cells, PARP inhibitors block PARP‑mediated DNA repair (BER), exploiting homologous recombination deficiency, carboplatin induces DNA crosslinks, bevacizumab blocks VEGF‑A signaling to inhibit angiogenesis. Targets: antigen‑positive tumor cells (ADC), DNA damage response/PARP1 pathway and HR‑deficient tumor cells (PARPi, platinum), and tumor vasculature/VEGF pathway (bevacizumab). Indications: ovarian, lung adenocarcinoma, endometrial cancers.